Key facts
- Gila Therapeutics’s last known valuation is $13.9M (Mar 2017).
- It has raised $6.6M across 1 recorded rounds; the latest was Later Stage VC in Apr 2025.
- Notable investors include Argonautic Ventures, iSelect Fund, Lateral Capital Management, Broadview Ventures, Harvard Business School Alumni Angels of Chicago — 9 tracked in total.
- Gila Therapeutics has filed 1 Form D with the SEC, most recently Nov 2021 ($1.3M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Gila Therapeutics
Funding rounds
1 roundsAbout Gila Therapeutics
Operator of a clinical-stage pharmaceutical company intended to treat obesity and prevent weight gain. The company develops and commercializes therapies for metabolic diseases, utilizing novel routes of administration, enabling individuals to lose weight and decrease calorie intake in a non-invasive and non-absorbed manner.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2014
- Employees
- 3
- Website
- gilatherapeutics.com/
- Ownership
- Privately Held (backing)
Gila Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gila Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gila Therapeutics in its N-PORT filings yet. We sweep new filings monthly.